Sun Pharmaceutical Industries (SUNPHARMA) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 consolidated sales reached INR 125,245 million, up 6.3% year-over-year, with net profit after tax increasing 40.2% year-over-year to INR 28,356 million and adjusted net profit up 20.9%.

• EBITDA rose 8.3% year-over-year to INR 36,076 million, with margins improving to 28.5%.

• India formulation sales grew 16.4% year-over-year, while U.S. sales declined 1% to $466 million; specialty business and emerging markets showed growth.

• The company completed the acquisition of all outstanding shares of Taro Pharmaceutical Industries Limited and received US FDA approval for LEQSELVITM (deuruxolitinib) for severe alopecia areata.

• EMA validated Nidlegy marketing application for melanoma.

Financial highlights

• Material cost was 21.4% of sales, lower year-over-year due to better product mix.

• Staff cost at 19.7% of sales; other expenses at 30.9% of sales, higher due to increased R&D and selling expenses.

• R&D investments increased to INR 7,940 million from INR 6,796 million in Q1FY24.

• EPS for the quarter was INR 11.8.

• Net cash position as of June 2024 was $2.3 billion.

Outlook and guidance

• Effective tax rate expected to rise for the full year due to reduced exemptions.

• R&D spend guidance remains at 8%-10% of sales, with a step-up expected in subsequent quarters.

• Specialty R&D pipeline includes 6 new active substances in clinical studies, with several regulatory and clinical milestones anticipated.

• Focus remains on volume-led growth in India and specialty launches in the U.S.